

### **REMARKS**

Reconsideration of the instant application is respectfully requested in view of the amendments above and the following remarks. Applicant thanks Examiner Wollenberger for the courtesy call to the Applicant's attorney and helpful suggestions to the claims provided during that interview. Accordingly, the claims have been amended according to these suggestions.

Briefly, the independent claims were amended to exclude the recitation of the mapping means and radiographic marker. The preambles were changed. Now the preambles recite delivery of small interfering RNA. Extraneous wording such as siRNA being capable of reducing ataxin-1 is also removed. Amendments to the dependent claims correct antecedent bases and remove awkward wording (i.e., the word "for" is removed from the phrase "mRNA encoding for ataxin-1 protein.")

Accordingly, amendments to the claims do not add new matter.

### **Amendments to the Drawings**

The Examiner noticed that the originally filed Figure 3 is different from the corresponding replacement drawing provided on April 29, 2004. The Examiner has also noted that in Fig 5, numeric reference "18" is not mentioned in the specification.

Accordingly, Applicants provide Replacement Sheets of the drawings. In the Replacement Sheets, the sheet corresponding to Fig. 3 corresponds to the originally filed Fig. 3. Since Fig. 3 recites sequence listings, in the replacement figure, these sequences have been identified by SEQ ID NO identifier. In the replacement figure 5, numeric reference "18" is removed.

Accordingly, no new matter has been introduced into the specification.

### **Amendments to the Sequence Listing**

Applicants thank the Examiner for noticing that the sequences in the originally filed Figure 3 need to be recited in Sequence Listing. In this Supplemental Response, Sequence Listing has been amended. Specifically, in its amended form, Sequence Listing includes the sequences from Figure 3 as SEQ ID NOs 24 and 25. This Sequence Listing does not contain any new matter and the contents of the paper and computer readable forms of Sequence Listing are identical.

### CONCLUSION

In view of the remarks above, Applicant submits that the pending claims are valid and favorable reconsideration and allowance are earnestly solicited. If, however, for any reason the Examiner does not believe that such action can be taken at this time, it is respectfully requested that the Examiner telephone Applicant's attorney at (609) 844-3021 to discuss any additional rejections.

The USPTO is authorized to charge Deposit Account No. 50-1943 for any charges in connection with this matter.

Date: July 14, 2009

Respectfully submitted,

By:           /Vyacheslav Vasilyev/            
Vyacheslav Vasilyev, Reg. No. 58,154  
Fox Rothschild LLP  
Princeton Pike Corporate Center  
997 Lenox Drive, Building 3  
Lawrenceville, NJ 08648-2311  
Telephone: 609-844-3021  
Facsimile: 609-896-1469  
*Attorney for the applicant(s)*